Clarivate amends 8-K with pro forma financials for $600 million LS&H sale to Altaris affiliate
CLVT•Clarivate amended a Form 8-K detailing its completed $600 million sale of its Life Sciences and Healthcare business to an Altaris affiliate. It received $488.4 million in cash at closing, net of closing costs and working-capital adjustments.
1. Sale details
The transaction closed on Oct. 6, 2026. It includes a $75 million unsecured senior note and $25 million in deferred cash consideration due no later than Jan. 31, 2028. Clarivate said the divestiture represents a strategic shift and qualifies for discontinued-operations accounting in the third quarter of 2026. It does not expect the gain or loss on sale to be material.
